Skip to main content

Advertisement

Log in

Immunoadsorption in dermatology

  • Mini Review
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Immunoadsorption (IA), also termed immunoapheresis, has been established as effective and specific tool advantageous to plasmapheresis to remove immunoglobulin and immune complexes and in cytapheresis, immune cells from the circulation. IA was successfully used in various autoantibody-mediated diseases, e.g. acquired hemophilia, myasthenia gravis, dilated cardiomyopathy, and Guillain–Barré syndrome. In dermatology, IA has been applied as an effective adjuvant treatment for autoimmune bullous diseases. Autoimmune blistering disorders are a heterogeneous group of diseases that are associated with autoantibodies to desmosomal (pemphigus group) and basal membrane zone proteins (pemphigoid group, epidermolysis bullosa acquisita). Because the pathogenic relevance of autoantibodies was clearly demonstrated in the majority of these disorders, removal of autoantibodies, therefore, appears to be a rational therapeutic approach for these patients. IA has been shown to effectively lower the autoantibody levels and leads to rapid clinical responses in patients with immunobullous disorders. Here, clinical effects and adverse events of IA in more than 50 reported patients with autoimmune blistering disorders are reviewed. In addition, an overview of the available IA systems and treatment protocols is provided and guidelines of a recent consensus of German, Austrian, and Swiss experts for the use of IA in autoimmune bullous diseases are summarized.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Amagai M, Hashimoto T, Shimizu N, Nishikawa T (1994) Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 94(1):59–67

    Article  CAS  PubMed  Google Scholar 

  2. Amagai M, Hashimoto T, Green KJ, Shimizu N, Nishikawa T (1995) Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol 104(6):895–901

    Article  CAS  PubMed  Google Scholar 

  3. Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, Kaneko F, Izaki S, Tamaki K, Ikezawa Z, Takigawa M, Seishima M, Tanaka T, Miyachi Y, Katayama I, Horiguchi Y, Miyagawa S, Furukawa F, Iwatsuki K, Hide M, Tokura Y, Furue M, Hashimoto T, Ihn H, Fujiwara S, Nishikawa T, Ogawa H, Kitajima Y, Hashimoto K (2009) A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 60(4):595–603

    Article  PubMed  Google Scholar 

  4. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA (1982) Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 306(20):1189–1196

    CAS  PubMed  Google Scholar 

  5. Anhalt GJ (2004) Paraneoplastic pemphigus. J Investig Dermatol Symp Proc 9(1):29–33

    Article  PubMed  Google Scholar 

  6. Bertram F, Brocker EB, Zillikens D, Schmidt E (2009) Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges 7(5):434–440

    PubMed  Google Scholar 

  7. Braun N, Bosch T (2000) Immunoadsorption, current status and future developments. Expert Opin Investig Drugs 9(9):2017–2038

    Article  CAS  PubMed  Google Scholar 

  8. Bystryn JC, Steinman NM (1996) The adjuvant therapy of pemphigus: an update. Arch Dermatol 132(2):203–212

    Article  CAS  PubMed  Google Scholar 

  9. Chams-Davatchi C, Valikhani M, Daneshpazhooh M, Esmaili N, Balighi K, Hallaji Z, Barzegari M, Akhiani M, Ghodsi Z, Mortazavi H, Naraghi Z (2005) Pemphigus: analysis of 1209 cases. Int J Dermatol 44(6):470–476

    Article  PubMed  Google Scholar 

  10. Cotterill JA, Barker DJ, Millard LG (1978) Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 98(2):243

    Article  CAS  PubMed  Google Scholar 

  11. Eming R, Rech J, Barth S, Kalden JR, Schuler G, Harrer T, Hertl M (2006) Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 212(2):177–187

    Article  PubMed  Google Scholar 

  12. Felix SB, Staudt A (2008) Immunoadsorption as treatment option in dilated cardiomyopathy. Autoimmunity 41(6):484–489

    Article  CAS  PubMed  Google Scholar 

  13. Freedman J, Garvey MB (2004) Immunoadsorption of factor VIII inhibitors. Curr Opin Hematol 11(5):327–333

    Article  CAS  PubMed  Google Scholar 

  14. Frost N, Messer G, Fierlbeck G, Risler T, Lytton SD (2005) Treatment of pemphigus vulgaris with protein A immunoadsorption: case report of long-term history showing favorable outcome. Ann N Y Acad Sci 1051:591–596

    Article  PubMed  Google Scholar 

  15. Gaubitz M, Schneider KM (2003) Immunoadsorption in systemic lupus erythematosus: different techniques and their current role in medical therapy. Ther Apher Dial 7(2):183–188

    Article  PubMed  Google Scholar 

  16. Genberg H, Kumlien G, Wennberg L, Tyden G (2007) Long-term results of ABO-incompatible kidney transplantation with antigen-specific immunoadsorption and rituximab. Transplantation 84(12 Suppl):S44–S47

    Article  CAS  PubMed  Google Scholar 

  17. Genberg H, Kumlien G, Wennberg L, Berg U, Tyden G (2008) ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation 85(12):1745–1754

    Article  CAS  PubMed  Google Scholar 

  18. Guillaume JC, Roujeau JC, Morel P, Doutre MS, Guillot B, Lambert D, Lauret P, Lorette G, Prigent F, Triller R et al (1988) Controlled study of plasma exchange in pemphigus. Arch Dermatol 124(11):1659–1663

    Article  CAS  PubMed  Google Scholar 

  19. Gunther C, Laske J, Frind A, Julius U, Pfeiffer C (2008) Successful therapy of pemphigus vulgaris with immunoadsorption using the TheraSorbtrade mark adsorber. J Dtsch Dermatol Ges

  20. Herrero-Gonzalez JE, Sitaru C, Klinker E, Brocker EB, Zillikens D (2005) Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption. Clin Exp Dermatol 30(5):519–522

    Article  CAS  PubMed  Google Scholar 

  21. Hiepe F, Pfuller B, Wolbart K, Bruns A, Leinenbach HP, Hepper M, Schossler W, Otto V (1999) C1q: a multifunctional ligand for a new immunoadsorption treatment. Ther Apher 3(3):246–251

    CAS  PubMed  Google Scholar 

  22. Ino N, Kamata N, Matsuura C, Shinkai H, Odaka M (1997) Immunoadsorption for the treatment of bullous pemphigoid. Ther Apher 1(4):372–376

    Article  CAS  PubMed  Google Scholar 

  23. Iwata H, Kamio N, Aoyama Y, Yamamoto Y, Hirako Y, Owaribe K, Kitajima Y (2009) IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment. J Invest Dermatol 129(4):919–926

    Article  CAS  PubMed  Google Scholar 

  24. Kaczmarek I, Deutsch MA, Sadoni S, Brenner P, Schmauss D, Daebritz SH, Weiss M, Meiser BM, Reichart B (2007) Successful management of antibody-mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review. J Heart Lung Transplant 26(5):511–515

    Article  PubMed  Google Scholar 

  25. Kadar JG, Borberg H (1990) Biocompatibility of extracorporeal immunoadsorption systems. Transfus Sci 11(2):223–239

    Article  CAS  PubMed  Google Scholar 

  26. Kasperkiewicz M, Hoppe U, Zillikens D, Schmidt E (2009) Relapse-associated autoantibodies to BP180 in a patient with anti-p200 pemphigoid. Clin Exp Dermatol (in press)

  27. Kasperkiewicz M, Schmidt E, Rose C, Frambach, Anemüller W, Grabbe J, Ludwig R, Zillikens D (2009) Immunadsorption bei Patienten mit schwerster atopischer Dermatitis und exzessiv erhöhten peripheren Serum-IgE-Spiegeln. 82. Jahrestagung der Norddeutschen Dermatologischen Gesellschaft. 02.04.09.2009, Halle (Saale) (abstract)

  28. Knobl P, Derfler K (1999) Extracorporeal immunoadsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX. Vox Sang 77(Suppl 1):57–64

    CAS  PubMed  Google Scholar 

  29. Kumlien G, Ullstrom L, Losvall A, Persson LG, Tyden G (2006) Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies. Transfusion 46(9):1568–1575

    Article  CAS  PubMed  Google Scholar 

  30. Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J (2008) Bullous pemphigoid and pemphigus vulgaris–incidence and mortality in the UK: population based cohort study. BMJ 337:a180

    Google Scholar 

  31. Lazarova Z, Yee C, Darling T, Briggaman RA, Yancey KB (1996) Passive transfer of anti-laminin 5 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest 98(7):1509–1518

    Article  CAS  PubMed  Google Scholar 

  32. Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA, Giudice GJ (1993) A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 92(5):2480–2488

    Article  CAS  PubMed  Google Scholar 

  33. Liu Z, Diaz LA, Swartz SJ, Troy JL, Fairley JA, Giudice GJ (1995) Molecular mapping of a pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid. J Immunol 155(11):5449–5454

    CAS  PubMed  Google Scholar 

  34. Liumbruno GM, Centoni PE, Molfettini P, Ceretelli S, Ceccarini M, Bachini L, Pomponi A, Bagnoni G, Vitolo M, Eberle O, Biondi A, Sodini ML (2006) Lymphocytapheresis in the treatment of psoriasis vulgaris. J Clin Apher 21(3):158–164

    Article  PubMed  Google Scholar 

  35. Luftl M, Stauber A, Mainka A, Klingel R, Schuler G, Hertl M (2003) Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 149(3):598–605

    Article  CAS  PubMed  Google Scholar 

  36. Marazza G, Pham HC, Scharer L, Pedrazzetti PP, Hunziker T, Trueb RM, Hohl D, Itin P, Lautenschlager S, Naldi L, Borradori L (2009) Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 161(4):861–868

    Article  CAS  PubMed  Google Scholar 

  37. Marn Pernat A, Buturovic-Ponikvar J, Svigelj V, Ponikvar R (2009) Guillain–Barre syndrome treated by membrane plasma exchange and/or immunoadsorption. Ther Apher Dial 13(4):310–313

    Article  PubMed  CAS  Google Scholar 

  38. Matic G, Hofmann D, Winkler R, Tiess M, Michelsen A, Schneidewind JM, Hebestreit G, Keysser M, Muller W, Kinze EM, Ramlow W (2000) Removal of immunoglobulins by a protein A versus an antihuman immunoglobulin G-based system: evaluation of 602 sessions of extracorporeal immunoadsorption. Artif Organs 24(2):103–107

    Article  CAS  PubMed  Google Scholar 

  39. Mitsuyama K, Sata M (2009) Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of action. Cytotherapy 11(2):229–237

    Article  CAS  PubMed  Google Scholar 

  40. Mulyowa GK, Jaeger G, Kabakyenga J, Brocker EB, Zillikens D, Schmidt E (2006) Autoimmune subepidermal blistering diseases in Uganda: correlation of autoantibody class with age of patients. Int J Dermatol 45(9):1047–1052

    Article  PubMed  Google Scholar 

  41. Nagel A, Hertl M, Eming R (2009) B-cell-directed therapy for inflammatory skin diseases. J Invest Dermatol 129(2):289–301

    Article  CAS  PubMed  Google Scholar 

  42. Naito K, Morioka S, Ogawa H (1982) The pathogenic mechanisms of blister formation in bullous pemphigoid. J Invest Dermatol 79(5):303–306

    Article  CAS  PubMed  Google Scholar 

  43. Niedermeier A, Eming R, Pfutze M, Neumann CR, Happel C, Reich K, Hertl M (2007) Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol 143(2):192–198

    Article  CAS  PubMed  Google Scholar 

  44. Norda R, Stegmayr BG (2003) Therapeutic apheresis in Sweden: update of epidemiology and adverse events. Transfus Apher Sci 29(2):159–166

    Article  PubMed  Google Scholar 

  45. Ogata K, Yasuda K, Matsushita M, Kodama H (1999) Successful treatment of adolescent pemphigus vulgaris by immunoadsorption method. J Dermatol 26(4):236–239

    CAS  PubMed  Google Scholar 

  46. Ohji S, Nomura K (2008) The indication of steroid pulse therapy and apheresis therapy for multiple sclerosis. Nippon Rinsho 66(6):1127–1132

    PubMed  Google Scholar 

  47. Pfutze M, Eming R, Kneisel A, Kuhlmann U, Hoyer J, Hertl M (2009) Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology 218(3):237–245

    Article  PubMed  CAS  Google Scholar 

  48. Pisanti S, Sharav Y, Kaufman E, Posner LN (1974) Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol 38(3):382–387

    Article  CAS  PubMed  Google Scholar 

  49. Poullin P, Announ N, Mugnier B, Guis S, Roudier J, Lefevre P (2005) Protein A-immunoadsorption (Prosorba column) in the treatment of rheumatoid arthritis. Joint Bone Spine 72(2):101–103

    Article  PubMed  Google Scholar 

  50. Rech J, Hueber AJ, Kallert S, Leipe J, Kalden JR, Beck M, Schett G, Schulze-Koops H (2008) Remission of demyelinating polyneuropathy with immunoadsorption, low dose corticosteroids and anti-CD20 monoclonal antibody. Ther Apher Dial 12(3):205–208

    Article  CAS  PubMed  Google Scholar 

  51. Ronspeck W, Brinckmann R, Egner R, Gebauer F, Winkler D, Jekow P, Wallukat G, Muller J, Kunze R (2003) Peptide based adsorbers for therapeutic immunoadsorption. Ther Apher Dial 7(1):91–97

    Article  PubMed  Google Scholar 

  52. Roujeau JC, Revuz J, Touraine R, Joneau-Fabre M, Mannoni P (1979) Cortico-resistant bullous pemphigoid: favorable results with plasmapheresis. Nouv Presse Med 8(41):3362

    CAS  PubMed  Google Scholar 

  53. Roujeau JC, Andre C, Joneau Fabre M, Lauret P, Flechet ML, Kalis B, Revuz J, Touraine R (1983) Plasma exchange in pemphigus: uncontrolled study of ten patients. Arch Dermatol 119(3):215–221

    Article  CAS  PubMed  Google Scholar 

  54. Sakai Y, Sakai S, Otsuka T, Ohno D, Murasawa T, Munakata K, Mizuno K (2009) Efficacy of high-throughput leukocytapheresis for rheumatoid arthritis with a reduced response to infliximab. Ther Apher Dial 13(3):179–185

    Article  PubMed  Google Scholar 

  55. Sawada K, Muto T, Shimoyama T, Satomi M, Sawada T, Nagawa H, Hiwatashi N, Asakura H, Hibi T (2003) Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 9(4):307–321

    Article  CAS  PubMed  Google Scholar 

  56. Schiltz JR, Michel B (1976) Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. J Invest Dermatol 67(2):254–260

    Article  CAS  PubMed  Google Scholar 

  57. Schmidt E, Obe K, Brocker EB, Zillikens D (2000) Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 136(2):174–178

    Article  CAS  PubMed  Google Scholar 

  58. Schmidt E, Klinker E, Opitz A, Herzog S, Sitaru C, Goebeler M, Mansouri Taleghoni B, Brocker EB, Zillikens D (2003) Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 148(6):1222–1229

    Article  CAS  PubMed  Google Scholar 

  59. Schmidt E, Brocker EB, Goebeler M (2008) Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 34(1):56–64

    Article  CAS  PubMed  Google Scholar 

  60. Schmidt E, Goebeler M, Zillikens D (2009) Rituximab in severe pemphigus. Ann N Y Acad Sci 1173(9):683–691

    Article  CAS  PubMed  Google Scholar 

  61. Schmidt E, Zillikens D (2009) Research in practice: diagnosis of subepidermal autoimmune bullous disorders. J Dtsch Dermatol Ges 7(4):296–300

    PubMed  Google Scholar 

  62. Schoen H, Foedinger D, Derfler K, Amann G, Rappersberger K, Stingl G, Volc-Platzer B (1998) Immunoapheresis in paraneoplastic pemphigus. Arch Dermatol 134(6):706–710

    Article  CAS  PubMed  Google Scholar 

  63. Shimanovich I, Herzog S, Schmidt E, Opitz A, Klinker E, Brocker EB, Goebeler M, Zillikens D (2006) Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 31(6):768–774

    Article  CAS  PubMed  Google Scholar 

  64. Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D (2008) Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 158(2):382–388

    Article  CAS  PubMed  Google Scholar 

  65. Shimanovich I, Bohmke AK, Westermann L, Kramer J, Zillikens D, Schmidt E (2009) Successful treatment of severe pemphigus with the combination of immunoadsorption and rituximab. J Invest Dermatol 129:S97

    Google Scholar 

  66. Sitaru C, Kromminga A, Hashimoto T, Brocker EB, Zillikens D (2002) Autoantibodies to type VII collagen mediate Fcgamma-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin. Am J Pathol 161(1):301–311

    CAS  PubMed  Google Scholar 

  67. Sitaru C, Schmidt E, Petermann S, Munteanu LS, Brocker EB, Zillikens D (2002) Autoantibodies to bullous pemphigoid antigen 180 induce dermal–epidermal separation in cryosections of human skin. J Invest Dermatol 118(4):664–671

    Article  CAS  PubMed  Google Scholar 

  68. Sitaru C, Mihai S, Otto C, Chiriac MT, Hausser I, Dotterweich B, Saito H, Rose C, Ishiko A, Zillikens D (2005) Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest 115(4):870–878

    CAS  PubMed  Google Scholar 

  69. Sitaru C, Chiriac MT, Mihai S, Buning J, Gebert A, Ishiko A, Zillikens D (2006) Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J Immunol 177(5):3461–3468

    CAS  PubMed  Google Scholar 

  70. Soerensen H, Schneidewind-Mueller JM, Lange D, Kashiwagi N, Franz M, Yokoyama T, Ramlow W (2006) Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus. Rheumatol Int 26(5):409–415

    Article  PubMed  Google Scholar 

  71. Sondergaard K, Carstens J, Jorgensen J, Zachariae H (1995) The steroid-sparing effect of long-term plasmapheresis in pemphigus. Acta Derm Venereol 75(2):150–152

    CAS  PubMed  Google Scholar 

  72. Tan-Lim R, Bystryn JC (1990) Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol 22(1):35–40

    Article  CAS  PubMed  Google Scholar 

  73. Turner MS, Sutton D, Sauder DN (2000) The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol 43(6):1058–1064

    Article  CAS  PubMed  Google Scholar 

  74. Wallukat G, Muller J, Hetzer R (2002) Specific removal of beta1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med 347(22):1806

    Article  PubMed  Google Scholar 

  75. Waschke J (2008) The desmosome and pemphigus. Histochem Cell Biol 130(1):21–54

    Article  CAS  PubMed  Google Scholar 

  76. Wohrl S, Geusau A, Karlhofer F, Derfler K, Stingl G, Zillikens D (2003) Pemphigoid gestationis: treatment with immunoapheresis. J Dtsch Dermatol Ges 1(2):126–130

    PubMed  Google Scholar 

  77. Woodley DT, Ram R, Doostan A, Bandyopadhyay P, Huang Y, Remington J, Hou Y, Keene DR, Liu Z, Chen M (2006) Induction of epidermolysis bullosa acquisita in mice by passive transfer of autoantibodies from patients. J Invest Dermatol 126(6):1323–1330

    Article  CAS  PubMed  Google Scholar 

  78. Zillikens D, Derfler K, Eming R, Fierlbeck G, Goebeler M, Hertl M, Hofmann SC, Karlhofer F, Kautz O, Nitschke M, Opitz A, Quist S, Rose C, Schanz S, Schmidt E, Shimanovich I, Michael M, Ziller F (2007) Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 5(10):881–887

    Article  PubMed  Google Scholar 

[Related articles recently published in the Archives of Dermatological Research (selected by the journal’s editorial staff)]

  1. Abreu-Velez AM, Howard MS, Hashimoto K, Hashimoto T (2009) Autoantibodies to sweat glands detected by different methods in serum and in tissue from patients affected by a new variant of endemic pemphigus foliaceus. Arch Dermatol Res 301:711–718

    Article  CAS  PubMed  Google Scholar 

  2. Gaines E, Werth VP (2008) Development of outcome measures for autoimmune dermatoses. Arch Dermatol Res 300:3–9

    Article  CAS  PubMed  Google Scholar 

  3. Leighty L, Li N, Diaz LA, Liu Z (2007) Experimental models for the autoimmune and inflammatory blistering disease: bullous pemphigoid. Arch Dermatol Res 299:417–422

    Article  CAS  PubMed  Google Scholar 

  4. Nancy AL, Yehuda S (2009) Prediction and prevention of autoimmune skin disorders. Arch Dermatol Res 301:57–64

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This work was supported by the Schleswig–Holstein Cluster of Excellence in Inflammation Research (DFG EXC 306/1).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Enno Schmidt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmidt, E., Zillikens, D. Immunoadsorption in dermatology. Arch Dermatol Res 302, 241–253 (2010). https://doi.org/10.1007/s00403-009-1024-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-009-1024-9

Keywords

Navigation